In This Issue
In the Spotlight
In T-ALL, a targetable SIRT1-KAT7 axis is revealed whereby NOTCH1 binding to an enhancer transcriptionally upregulates SIRT1, and SIRT1 promotes leukemia progression by deacetylating and activating KAT7.
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
An imbalance between activating and repressive ETS transcription factors transforms genomic GGAA tandem repeats into leukemia-specific enhancers that drive the unique gene expression signature of ETV6-RUNX1+ B-ALL.
Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses
Exosomes produced in the leukemia microenvironment inhibit CD8+ T cell-mediated antitumor immunity by immune checkpoint interactions and miRNA transfer sustaining CLL development in mouse models.
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Novel mouse models of Myd88-driven DLBCL serve as preclinical platforms to evaluate combined BTK/BCL2 inhibition and immune-therapeutic approaches.
Acknowledgment to Reviewers